Globe Newswire
Globe Newswire
More Globe Newswire
View Older Stories View Newer Stories-
Canadian North Resources Inc. Provides Update on Normal Course Issuer Bid
-
JACC: Heart Failure Paper Reports Promising Findings of Aquadex Therapy in Updated AVOID-HF Study Analysis
-
Bonus Biogroup Announces U.S. Food and Drug Administration (FDA) Clearance of an Investigational New Drug (IND) Application for MesenCure™ Phase III Clinical Study in Respiratory Distress
-
Dominion Lending Centres Inc. Enters into Marketing Partnership Agreement with RE/MAX Canada
-
Sprott Launches Active Gold & Silver Miners ETF
-
VYNE Therapeutics to Participate in March Investor Conferences
-
Daré Bioscience and Theramex Announce Co-Development and Licensing Agreement for a Potential Biodegradable Long-Acting Contraceptive Implant
-
Better Choice Company Agrees in Principle to Licensing Agreement in Asia for its Halo Elevate® Brand
-
AgEagle Aerial Systems Announces Evolution of eBee VISION Application Software Featuring Next Generation Mapping and Tactical Advantages
-
ProPhase Labs Announces Excellent Progress with Crown Medical Collections Targeting Over $50 Million in Net Near-Term Cash Recovery from COVID-19 Receivables
-
Conduit Progresses Phase II of its AI Initiative with Sarborg
-
Global Technologies, Ltd. Announces Second Consecutive Quarter of Record-Breaking Revenue and Profitability Following Successful Reorganization
-
GCL and 4Divinity Sign Memorandum of Understanding with Sword Panda for Global Publishing Rights of “Yuan Gong’s Sword: Awakening”
-
KnowBe4 Earns a Top Spot on G2’s 2025 Best Software Awards
-
PDS Biotech to Participate at B. Riley Securities Precision Oncology & Radiopharma Conference 2025
-
Foremost Clean Energy Reports Multiple Intercepts of Uranium Mineralization from Hatchet Assays
-
Anaplan achieves significant milestones in its multi-year business transformation
-
Lisata Therapeutics to Report Full Year 2024 Financial Results and Provide a Business Update on Thursday, February 27, 2025
-
Oxford Lane Capital Corp. Prices Public Offering of $165,000,000 7.95% Notes Due 2032
-
Good Supply Introduces New Monsters Resin Vapes: Full Spectrum Highs
-
Assembly Biosciences Reports Positive Interim Phase 1a Results from Clinical Trial Evaluating Long-Acting Helicase-Primase Inhibitor ABI-1179 in Development for Recurrent Genital Herpes
-
NevGold Discovers Samples With Up to 10% Antimony at the Limousine Butte Gold-Antimony Project in Nevada
-
authID's Biometric Authentication and Groundbreaking Privacy Solutions Spotlighted in New Prism Project Report
-
Armlogi Advances Supply Chain Solutions with Roadie, a UPS Company, Expanding Last-Mile Delivery Coverage to 97% of U.S.
-
Talkspace Announces Fourth Quarter and Full Year 2024 Results
-
Monarch Private Capital Powers Into 2025 With Record Growth, Innovation, and a Bold Vision for the Future
-
FLYR Appoints Steven Berns as Chief Financial and Administrative Officer
-
BriteCore Solution Marketplace Expands with Five New Vendor Integrations
-
Tectonic Therapeutic to Participate in March Investor Conferences
-
City of Columbus Selects Voltus as its Exclusive Demand Response Provider
-
Aterian Issues Letter to Shareholders
-
Orchestra BioMed to Present at Upcoming Investor Conferences
-
FAVO Capital to Attend 14th Annual Global Fund Finance Symposium in Miami
-
Growth in Originations Expected Across Multiple Credit Products in 2025
-
T-knife Therapeutics Welcomes Dr. Sophie Papa to its Board of Directors
-
HighSpeedInternet.com Releases Fifth Annual Internet Service Provider (ISP) Review
-
UPSTACK Acquires IT Advisory Firm V3 Technology
-
DIRECTV Advertising and Magnite Enhance Live Streaming Programmatic Demand During Peak Viewing Events
-
STACK Infrastructure Appoints Matt VanderZanden as President
-
Fiverr Launches a Freelancer Equity Program to Give Direct Stake in the Business
-
Pacira to Report 2024 Financial Results on Thursday February 27, 2025
-
Boehringer Ingelheim and partners start clinical development of a first-in-class, inhaled gene therapy for people with cystic fibrosis
-
EPKINLY® (epcoritamab) Approved by Japan Ministry of Health, Labour and Welfare for Additional Indication as a Treatment for Relapsed or Refractory Follicular Lymphoma
-
Natural gas remains the crucial bridge in the energy transition, yet challenges persist
-
Interim Management Report covering H1 2024/25
-
ParaZero Unlocks Growth Opportunities After Achieving European Regulatory Compliance for its SafeAir Systems
-
Aptose Announces Positive Clinical Safety Review Committee (CSRC) Approval to Dose Escalate in Phase 1/2 Tuscany Trial of Frontline Triple Drug Therapy with Tuspetinib Amid Complete Responses and Favo
-
Gold-Rich Cobalt-Copper Mineralization at CAS Property Strengthens Electra’s Idaho Exploration Strategy
-
Ardelyx Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update
-
FTI Consulting Reports Fourth Quarter and Full Year 2024 Financial Results
